JNJ-87801493

Phase 1Small molecule

Johnson & Johnson

JNJ-87801493 is one of 28 small molecule programs targeting Leukemia, Myeloid, Acute. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Leukemia, Myeloid, AcuteEnrolling by invitation

Lymphoma, Non-HodgkinActive, not recruiting

Leukemia, Myeloid, AcutePhase 1

Enrolling by invitation

Lymphoma, Non-HodgkinPhase 1

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Leukemia, Myeloid, Acute

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 3

3 2

Peony

Takeda

Phase 3

1 3

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 3

4 4

Cytosar

Teva

Phase 2

2 5

Fludara

Sanofi

Phase 2

1 6

Trexall

Alnylam Pharmaceuticals

Phase 2

1 7

Bleximenib

Johnson & Johnson

Phase 3

2 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

1 9

Revuforj

SSyndax Pharmaceuticals

Phase 2

1 10

ORCA-T

OOrca Biosystems, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Active, not recruiting

Lymphoma, Non-Hodgkin

NCT06139406

Q3 2028

Phase 1Recruiting

Lymphoma, Non-Hodgkin

NCT07308132

Clinical

Trials by Indication[1]

Lymphoma, Non-Hodgkin2 trials

A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT07308132·130 enrolled

A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06139406·70 enrolled

Leukemia, Myeloid, Acute1 trial

An Open Label, Rollover Platform Study for Continued Study Treatment and Ongoing Safety Monitoring

Enrolling by invitation· Johnson & Johnson logo

Johnson & Johnson·Phase 1·NCT06788509·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for JNJ-87801493. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JNJ-87801493 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JNJ-87801493. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Johnson & Johnson

JNJ-87801493

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q3 2028

Trials by Indication[1]

Lymphoma, Non-Hodgkin2 trials

Leukemia, Myeloid, Acute1 trial

References

Drug Info

Quick Facts

Related News